

Gastrointestinal Stromal Tumors - Pipeline Insight, 2021

<https://marketpublishers.com/r/G01B1062777EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: G01B1062777EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Gastrointestinal Stromal Tumors - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Gastrointestinal Stromal Tumors Understanding

Gastrointestinal Stromal Tumors: Overview

Gastrointestinal stromal tumors (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients

can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.

'Gastrointestinal Stromal Tumors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastrointestinal Stromal Tumors pipeline landscape is provided which includes the disease overview and Gastrointestinal Stromal Tumors treatment guidelines. The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Gastrointestinal Stromal Tumors.

Gastrointestinal Stromal Tumors Emerging Drugs Chapters

This segment of the Gastrointestinal Stromal Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastrointestinal Stromal Tumors Emerging Drugs

Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived

growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors.

DS 6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in phase 1 of clinical development for the treatment of Gastrointestinal Stromal Tumors.

Further product details are provided in the report

Gastrointestinal Stromal Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Gastrointestinal Stromal Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastrointestinal Stromal Tumors

There are approx. 20+ key companies which are developing the therapies for Gastrointestinal Stromal Tumors. The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastrointestinal Stromal Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastrointestinal Stromal Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastrointestinal Stromal Tumors drugs.

Gastrointestinal Stromal Tumors Report Insights

Gastrointestinal Stromal Tumors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Gastrointestinal Stromal Tumors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Gastrointestinal Stromal Tumors drugs?

How many Gastrointestinal Stromal Tumors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastrointestinal Stromal Tumors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastrointestinal Stromal Tumors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Gastrointestinal Stromal Tumors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Jiangsu Hengrui Medicine

Daiichi Sankyo Company

Cogent Biosciences

Advenchen Laboratories

Chia Tai Tianqing Pharmaceutical Group

AB Science

Immunicum AB

Novartis

Bristol-Myers Squibb

Hanmi Pharmaceutical Company Limited

GlaxoSmithKline

Ascentage Pharma

Takeda

Array BioPharma

Plexxikon

Arog Pharmaceuticals

Xencor, Inc.

DNATRIX, Inc.

Taiho Pharmaceutical

Onyx Pharmaceuticals

Exelixis

Allarity Therapeutics

Key Products

Famitinib

DS 6157

PLX9486

Anlotinib

Masitinib

Intuvax

Dovitinib

Ipilimumab

L-carnitine

Pazopanib

Nilotinib

HQP1351

PDR001

Ponatinib

MEK162

Crenolanib besylate

XmAb18087

TNO155

DNX-2440

Pimitespib

Palbociclib

Cabozantinib

Pamufetini

Contents

Introduction

Executive Summary

Gastrointestinal Stromal Tumors: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Gastrointestinal Stromal Tumors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Gastrointestinal Stromal Tumors companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Gastrointestinal Stromal Tumors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Famitinib: Jiangsu Hengrui Medicine

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

DS 6157: Daiichi Sankyo Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Gastrointestinal Stromal Tumors Key Companies

Gastrointestinal Stromal Tumors Key Products

Gastrointestinal Stromal Tumors- Unmet Needs

Gastrointestinal Stromal Tumors- Market Drivers and Barriers

Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion

Gastrointestinal Stromal Tumors Analyst Views

Gastrointestinal Stromal Tumors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Gastrointestinal Stromal Tumors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Gastrointestinal Stromal Tumors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Gastrointestinal Stromal Tumors - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/G01B1062777EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G01B1062777EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970